Cardio Diagnostics (NASDAQ:CDIO) Issues Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) released its quarterly earnings results on Wednesday. The company reported ($0.98) earnings per share for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 30,465.10% and a negative return on equity of 72.78%.

Cardio Diagnostics Price Performance

CDIO traded down $0.07 during trading on Wednesday, reaching $3.74. 6,903 shares of the company’s stock were exchanged, compared to its average volume of 54,607. The stock has a market capitalization of $6.58 million, a P/E ratio of -1.00 and a beta of 2.89. The company’s fifty day simple moving average is $4.07 and its 200-day simple moving average is $4.58. Cardio Diagnostics has a 1 year low of $3.22 and a 1 year high of $53.10.

Wall Street Analyst Weigh In

CDIO has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Wednesday, October 8th. Wall Street Zen raised Cardio Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.